


## REMARKS

Claims 45 and 70 have been corrected to indicate claims' status. Also enclosed is a corrected marked-up version of claims 45 and 70. The correction addresses an issue of parenthetical expression indicating the status of the claims inadvertently omitted in the clean set and in the marked-up version of the amendments made to the claims by the amendment filed February 26, 2002.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing 532732000201. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: July 26, 2002

Respectfully submitted,

By: 

Peng Chen  
Registration No. 43,543

Morrison & Foerster LLP  
3811 Valley Centre Drive  
Suite 500  
San Diego, California 92130-2332  
Telephone: (858) 720-5117  
Facsimile: (858) 720-5125

**CORRECTED VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**In the Claims:**

45. (Amended) A method of preparing a pharmaceutical composition or therapeutic vaccine, said method comprising the steps of:

(a) providing a plurality of hepatocellular carcinoma cells, lymphoma cells, colon carcinoma cells or gastric cancer cells;

(b) treating said hepatocellular carcinoma cells, lymphoma cells, colon carcinoma cells or gastric cancer cells to increase the levels of [CD28, 4-1BB, or CTLA-4] primary or costimulatory molecules in said cells;

(c) providing a plurality of a bispecific monoclonal antibodies, each of said antibodies comprising a binding site for a CD28, 4-1BB or CTLA-4 molecule on the surface of T cells in a patient mammal and a binding site for a gp55, gp95, gp115 or gp210 antigen;

(d) attaching said bispecific monoclonal antibodies to said cells; and

(e) thereafter collecting a pharmaceutically effective amount of said cells with said bispecific monoclonal antibodies attached thereto; wherein said steps (c) and (d) are performed either before or after said step (b).

70. (Amended) An immunogenic composition, comprising:

a pharmaceutically effective amount of one or more isolated autologous hepatocellular carcinoma cells, lymphoma cells, colon carcinoma cells or gastric cancer cells which express one

or more [CD28, 4-1BB, or CTLA-4] primary or costimulatory molecules at a level higher than in said cells in a patient mammal; and

a pharmaceutically effective amount of one or more bispecific monoclonal antibodies comprising a binding site for a CD28, 4-1BB or CTLA-4 molecule on the surface of T cells in a patient mammal, and a binding site for a gp55, gp95, gp115, or gp210 antigen, wherein said bispecific monoclonal antibodies are attached to said cells, and wherein said composition is substantially free of bispecific monoclonal antibodies not attached to said cells.